OBJECTIVE: To determine the stability and functional significance of blood-brain barrier (BBB) integrity in patients with mild to moderate Alzheimer disease (AD). METHODS: Thirty-six patients (mean age 71 +/- 7 years) with mild to moderate AD (Mini-Mental State Examination [MMSE] 19 +/- 5) participated in a biomarker study involving clinical assessments, brain imaging, and CSF and plasma collection over 1 year. BBB integrity was assessed with the CSF-albumin index (CSF-AI). RESULTS: BBB disruption was present in an important subgroup of patients (n = 8/36, 22%) at all time points measured. CSF-AI was highly reproducible over 1 year with an intraclass correlation of 0.96. Age, sex, and APOE status did not correlate with CSF-AI. Vascular factors (blood pressure, Hachinski ischemia score, MR-derived white matter hyperintensity, body mass index) were not strongly associated with CSF-AI levels (p = 0.066). CSF/plasma IgG ratio correlated with CSF-AI in a manner indicating that peripheral IgG has greater access to the CNS in patients with an impaired BBB. Further evidence for the physiologic significance of the CSF-AI was noted in the form of correlations with rates of disease progression, including annual change on MMSE (r(2) = 0.11, p = 0.023), annual Clinical Dementia Rating sum-of-boxes change (r(2) = 0.29, p = 0.001), and annual ventricular volume change (r(2) = 0.17, p = 0.007). CONCLUSIONS: Blood-brain barrier (BBB) impairment is a stable characteristic over 1 year and present in an important subgroup of patients with Alzheimer disease. Age, gender, APOE status, vascular risk factors, and baseline Mini-Mental State Examination score did not explain the variability in BBB integrity. A role for BBB impairment as a modifier of disease progression is suggested by correlations between CSF-albumin index and measures of disease progression over 1 year.
OBJECTIVE: To determine the stability and functional significance of blood-brain barrier (BBB) integrity in patients with mild to moderate Alzheimer disease (AD). METHODS: Thirty-six patients (mean age 71 +/- 7 years) with mild to moderate AD (Mini-Mental State Examination [MMSE] 19 +/- 5) participated in a biomarker study involving clinical assessments, brain imaging, and CSF and plasma collection over 1 year. BBB integrity was assessed with the CSF-albumin index (CSF-AI). RESULTS: BBB disruption was present in an important subgroup of patients (n = 8/36, 22%) at all time points measured. CSF-AI was highly reproducible over 1 year with an intraclass correlation of 0.96. Age, sex, and APOE status did not correlate with CSF-AI. Vascular factors (blood pressure, Hachinski ischemia score, MR-derived white matter hyperintensity, body mass index) were not strongly associated with CSF-AI levels (p = 0.066). CSF/plasma IgG ratio correlated with CSF-AI in a manner indicating that peripheral IgG has greater access to the CNS in patients with an impaired BBB. Further evidence for the physiologic significance of the CSF-AI was noted in the form of correlations with rates of disease progression, including annual change on MMSE (r(2) = 0.11, p = 0.023), annual Clinical Dementia Rating sum-of-boxes change (r(2) = 0.29, p = 0.001), and annual ventricular volume change (r(2) = 0.17, p = 0.007). CONCLUSIONS: Blood-brain barrier (BBB) impairment is a stable characteristic over 1 year and present in an important subgroup of patients with Alzheimer disease. Age, gender, APOE status, vascular risk factors, and baseline Mini-Mental State Examination score did not explain the variability in BBB integrity. A role for BBB impairment as a modifier of disease progression is suggested by correlations between CSF-albumin index and measures of disease progression over 1 year.
Authors: E A Mueller; M M Moore; D C Kerr; G Sexton; R M Camicioli; D B Howieson; J F Quinn; J A Kaye Journal: Neurology Date: 1998-12 Impact factor: 9.910
Authors: S M Greenberg; M E Briggs; B T Hyman; G J Kokoris; C Takis; D S Kanter; C S Kase; M S Pessin Journal: Stroke Date: 1996-08 Impact factor: 7.914
Authors: J T Moroney; E Bagiella; D W Desmond; V C Hachinski; P K Mölsä; L Gustafson; A Brun; P Fischer; T Erkinjuntti; W Rosen; M C Paik; T K Tatemichi Journal: Neurology Date: 1997-10 Impact factor: 9.910
Authors: A J Bayer; R Bullock; R W Jones; D Wilkinson; K R Paterson; L Jenkins; S B Millais; S Donoghue Journal: Neurology Date: 2005-01-11 Impact factor: 9.910
Authors: S Gilman; M Koller; R S Black; L Jenkins; S G Griffith; N C Fox; L Eisner; L Kirby; M Boada Rovira; F Forette; J-M Orgogozo Journal: Neurology Date: 2005-05-10 Impact factor: 9.910
Authors: Bruce R Reed; Natalie L Marchant; William J Jagust; Charles C DeCarli; Wendy Mack; Helena C Chui Journal: Neurobiol Aging Date: 2011-11-10 Impact factor: 4.673
Authors: Joanna M Karasinska; Franz Rinninger; Dieter Lütjohann; Piers Ruddle; Sonia Franciosi; Janine K Kruit; Roshni R Singaraja; Veronica Hirsch-Reinshagen; Jianjia Fan; Liam R Brunham; Nagat Bissada; Rajasekhar Ramakrishnan; Cheryl L Wellington; John S Parks; Michael R Hayden Journal: J Neurosci Date: 2009-03-18 Impact factor: 6.167